WESTLAKE VILLAGE, Calif. --(BUSINESS WIRE)--Sep. 10, 2026-- Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, localized therapies for inflammatory skin diseases, today announced that Bradley Burnam, Chief Executive Officer, and Stephen M.
Brings internationally recognized expertise in immunology, cytokine biology, host-microbe interactions and public health WESTLAKE VILLAGE, Calif. --(BUSINESS WIRE)--Sep. 9, 2026-- Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic
In-vivo study showed GX-03 reduced IL-36, a key early driver of the inflammatory cascade, by approximately 50%, IL-31, a major driver of itch, by nearly 68%, and IL-4, an important inflammatory cytokine, by 16.7% Findings support Turn’s approach of acting earlier in the inflammatory process, before
Interim Analysis Supports Expansion of GX-03 Phase 2 Study to a Broader Population of Atopic Dermatitis Patients, Including Patients with Moderate-to-Severe Lesions but Lower Overall Disease Extent Dr. Stephen M. Hahn, Former FDA Commissioner, Appointed Executive Clinical and Regulatory Lead First
Turn Therapeutics Returns to Nasdaq to Highlight Its Progress Since Its October 2025 Direct Listing WESTLAKE VILLAGE, Calif. --(BUSINESS WIRE)--Jul. 28, 2026-- Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory
Clinically meaningful efficacy observed across a broader spectrum of atopic dermatitis supports expansion of the ongoing Phase 2 program to prospectively evaluate patients across the full range of disease severity as defined by the Eczema Area and Severity Index (EASI) Comprehensive interim review
WESTLAKE VILLAGE, Calif. --(BUSINESS WIRE)--Jul. 6, 2026-- Turn Therapeutics, Inc. (NASDAQ: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory skin diseases, today announced it will host a live webcast on Tuesday, July 7, 2026, to present key
92.6% of GX-03-treated subjects achieved a 50% reduction in eczema severity in 4 weeks ( EASI -50); 70.4% achieved a 75% reduction in 4 weeks ( EASI -75); 44.4% achieved a 90% reduction in 4 weeks ( EASI -90); and 51.9% achieved a 90% reduction in 8 weeks ( EASI -90) Interim analysis informed
Study demonstrates statistically significant reduction in disease severity in a murine dermatitis model characterized by IL-36 expression First in a planned series of peer-reviewed publications exploring the scientific rationale and non-systemic mechanism underlying GX-03, currently in Phase 2
WESTLAKE VILLAGE, Calif. --(BUSINESS WIRE)--May 19, 2026-- Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, localized therapies for inflammatory skin diseases, today announced that Bradley Burnam, Chief Executive Officer, will present at the